Enterprise Value

277.9M

Cash

92.63M

Avg Qtr Burn

-16.03M

Short % of Float

4.96%

Insider Ownership

12.34%

Institutional Own.

61.81%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DANYELZA® (naxitamab-gqgk) Details
Spinal cord tumor, Neuroblastoma, Spinal cord injury, Cancer, Osteosarcoma

Approved

Quarterly sales

BLA

FDA meeting

Naxitamab + GM-CSF Details
Cancer, Neuroblastoma

Phase 2

Data readout

GD2-SADA Details
Cancer, Solid tumor/s, Melanoma, Small cell lung cancer, Sarcoma

Phase 1

Data readout

GD2-GD3 Vaccine Details
Rare diseases, Spinal cord tumor, Neuroblastoma, Cancer

Failed

Discontinued